On the basis of previous clinical studies, we performed a PRISMA-compliant meta-analysis of KLT combined with EGFR-TKI in patients with stage III/IV NSCLC (Figure 1) to assess the clinical efficacy, quality of life, immune function (including percentages of CD3+, CD4+, NK cells and the CD4+/CD8+ratio) and adverse events. Here, CD4 is linked to non-small cell lung carcinoma.